Abstract:Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a class of severe and chronic diseases of the gastrointestinal (GI) tract with recurrent symptoms and significant morbidity. Long-term persistence of chronic inflammation in IBD is a major contributing factor to neoplastic transformation and the development of colitis-associated colorectal cancer. Conversely, persistence of transmural inflammation in CD is associated with formation of fibrosing strictures, resulting in substantial morbidity. The recent introduction of biological response modifiers as IBD therapies, such as antibodies neutralizing tumor necrosis factor (TNF)-α, have replaced nonselective anti-inflammatory corticosteroids in disease management. However, a large proportion (~40%) of patients with the treatment of anti-TNF-α antibodies are discontinued or withdrawn from therapy because of (1) primary nonresponse, (2) secondary loss of response, (3) opportunistic infection, or (4) onset of cancer. Therefore, the development of novel and effective therapeutics targeting specific signaling pathways in the pathogenesis of IBD is urgently needed. In this comprehensive review, we summarize the recent advances in drug discovery of new small molecules in preclinical or clinical development for treating IBD that target biologically relevant pathways in mucosal inflammation. These include intracellular enzymes (Janus kinases, receptor interacting protein, phosphodiesterase 4, IκB kinase), integrins, G protein-coupled receptors (S1P, CCR9, CXCR4, CB2) and inflammasome mediators (NLRP3), etc. We will also discuss emerging evidence of a distinct mechanism of action, bromodomain-containing protein 4, an epigenetic regulator of pathways involved in the activation, communication, and trafficking of immune cells. We highlight their chemotypes, mode of actions, structure-activity relationships, characterizations, and their in vitro/in vivo activities and therapeutic potential. The perspectives on the relevant challenges, new opportunities, and future directions in this field are also discussed.

Role of Rho GTPases in Inflammatory Bowel Disease

Critical Roles of G Protein-Coupled Receptors in Regulating Intestinal Homeostasis and Inflammatory Bowel Disease

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Roles of G Protein-Coupled Receptors in Inflammatory Bowel Disease.

Role of miRNAs in pathogenesis of inflammatory bowel disease

RhoB affects colitis through modulating cell signaling and intestinal microbiome

Roles of Gut Bacteriophages in the Pathogenesis and Treatment of Inflammatory Bowel Disease

Role of MicroRNAs in Regulating T Cell Responses in Inflammatory Bowel Disease

Delineating the Role of Toll-Like Receptors in Inflammatory Bowel Disease.

The role of the Hippo pathway in the pathogenesis of inflammatory bowel disease

Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases

Role of Incretin Axis in Inflammatory Bowel Disease

Toll-Like Receptors And Inflammatory Bowel Disease

The Involvement of Glial Cell-Derived Neurotrophic Factor in Inflammatory Bowel Disease

Tripartite Motif Family Proteins in Inflammatory Bowel Disease: Mechanisms and Potential for Interventions

Advances in the Development of Rho GTPase Inhibitors

Role of long non-coding RNA in inflammatory bowel disease

S1PR2/RhoA/ROCK1 pathway promotes inflammatory bowel disease by inducing intestinal vascular endothelial barrier damage and M1 macrophage polarization

Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing

Mucin-Type O-Glycans: Barrier, Microbiota, and Immune Anchors in Inflammatory Bowel Disease

Exploring the role of IL-1β in inflammatory bowel disease pathogenesis